Lack of recurrence was evident by the fact that there was no urinary obstruction and no positive bone scans that indicate metastases. Eighteen of the patients were evaluated 6 months after starting PC-SPES treatment. Statistical analysis of the overall results showed that there was no PSA increase after PC-SPES treatment at 2 and 6 months. Side effects in these patients were nipple tenderness in two patients and leg clots requiring treatment with heparin in two patients. The early results from a phase II trial were presented at the annual meeting of the American Association for Clinical Oncology, May 1999, in Atlanta.
Toxicity is manageable.
Several publications in 1999 have addressed the use of PC-SPES in prostate cancer therapy. Dr. J. Geliebter et al. In reply, DiPaola et al. Dr. Geliebter et al. In reply to Dr. Geliebter, DiPaola et al.